dr Reddy’s Laboratories has introduced Methylprednisolone Sodium Succinate For Injection, USP, its generic equivalent of Solu-Medrol, to the US market.
The product, launched following US Food and Drug Administration (USFDA) approval, is indicated for various conditions including arthritis, blood disorders, allergic reactions and certain types of cancer.
A Pharmacia & Upjohn Company LLC brand, Solu-Medrol brand and generic, had US sales of approximately $144 million MAT for the trailing 12 months ended February 2022, said Dr. Reddy’s, citing figures from IQVIA Health.
The company said its Methylprednisolone Sodium Succinate For Injection, USP, comes in unit-dose vials of 40 mg/vial and 125 mg/vial, with each carton containing 25 vials; 500 mg and 1 g multidose vial, each carton contains 1 vial.
